Repigmentation in a patient with vitiligo on crisaborole 2% ointment

Abstract

Vitiligo is a common condition of autoimmune etiology resulting in skin depigmentation, which often causes psychological distress and reduced quality of life. Treatment options for vitiligo are limited. Phosphodiesterase type 4 (PDE4) is an intracellular enzyme, which is overactive in multiple inflammatory conditions, including vitiligo (Zaky et al, unpublished material). The oral PDE4 inhibitor apremilast is approved for psoriasis, psoriatic arthritis, and Behcet disease.1 In a recent case series, apremilast demonstrated some improvement in controlling the progression of vitiligo.

Topics & Concepts